We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2011 by ZhuGuangYing.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01391260
First Posted: July 11, 2011
Last Update Posted: August 2, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Beijing Cancer Hospital
Chinese Academy of Medical Sciences
Zhejiang Cancer Hospital
Fudan University
Renmin Hospital of Wuhan University
307 Hospital of PLA
Beijing Clinical Service Center
Information provided by:
ZhuGuangYing
July 7, 2011
July 11, 2011
August 2, 2011
July 2011
July 2012   (Final data collection date for primary outcome measure)
Response rate (RR) [ Time Frame: 1 year ]
Same as current
Complete list of historical versions of study NCT01391260 on ClinicalTrials.gov Archive Site
  • Progression free survival (PFS) [ Time Frame: 2 years ]
  • Overall survival (OS) [ Time Frame: 2 years ]
  • Quality of life (MD-Anderson questionnaire) [ Time Frame: 1 year ]
Same as current
Not Provided
Not Provided
 
Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)
A Phase II Trial of Radiation Therapy Combined With Iressa in Patients With Locally Advanced Non-small Cell Lung Cancer With Harboring Active EGFR Mutations
The purpose of this study is to access the effect and safety of radiotherapy combined whth Iressa for patients with locally advanced non-small cell lung cancer with harboring active EGFR mutations.
Worldwide more than half a million new cases of lung cancer are diagnosed annually. About 80% of these tumours are of non-small cell histological type. Surgery is the treatment of choice, but only about 20% of tumours are suitable for potentially curative resection. Concurrent chemoradiotherapy is the standard treatment for locally advanced NSCLC. When Iressa was used in the first-line treatment of advanced NSCLC with EGFR mutations positive, the 12-month rates of progression-free survival were 24.9%. Therefore, we speculate that the EGFR mutations in patients with locally advanced NSCLC, Gefitinib combined with radiotherapy may be better than chemoradiotherapy. We design the study to access the effect and safety of radiotherapy combined whth Iressa for patients with locally advanced non-small cell lung cancer with harboring active EGFR mutations.
Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Non-small Cell Lung Cancer
Other: Gefitinib
Radiation Therapy: 3D-CRT/IMRT 95%PTV 60-66Gy, 1.8-2.0Gy/f,5f/w; Gefitinib: 250 mg, Qd, p.o;
Other Name: Iressa
Experimental: Radiotherapy Combined With Gefitinib
Intervention: Other: Gefitinib
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
30
July 2017
July 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically confirmed diagnosis of non-squamous NSCLC; Stage ⅢA-ⅢB(not suitable for surgery) or stage Ⅳ(only single-site single transfer );
  • Untreated patients, or who completed ≤ 2 cycles of first-line chemotherapy (chemotherapy regimen: paclitaxel, docetaxel + cisplatin) within the previous month;
  • Patients with tumor EGFR mutation positive (exon 19 deletion mutation or exon 21 L858R substitution mutation);
  • Patients must be informed of the investigational nature of the study and must sign an informed consent form;
  • Presence of at least one measurable/evaluable according to RECIST criteria.
  • ECOG performance Status 0-2 ;
  • Patients must have a life expectancy > 12 weeks;
  • Patients with laboratory values as follows:WBC>4.0 x 109/L; ANC≥1.5 x 109/L; PLT≥100 x 109/L; HGB≥10 g/dL; CR≤1.5 x ULN; TBIL<1.5 x ULN; AST and ALT≤1.5 x ULN; LDH≤1.5 x ULN; AKP≤5 x ULN;
  • FEV 1≥1.0L and >50% Corresponding normal values;
  • Patient candidate to standard platinum-based chemotherapy;
  • Patients must be nonpregnant and non-lactating.Patients of childbearing potential must implement an effective method of contraception during the study. All female Patients, except those who are postmenopausal or surgically sterilized, must have a negative pre-study serum or urine pregnancy test.

Exclusion Criteria:

  • Any evidence of clinically active interstitial lung disease;
  • Diagnosis of any other malignancy during the last 5 years, except for in situ carcinoma of cervix uterine and squamous cell carcinoma of the skin;
  • Pregnancy or lactating;
  • Serious concomitant infection;
  • MI within preceding 6 months or symptomatic heart disease, including unstable angina, congestive heart failure or uncontrolled arrhythmia;
  • As judged by the investigator, any evidence of severe or uncontrolled systemic disease (eg, unstable or uncompensated respiratory, cardiac, hepatic, or renal disease);
  • Patients who are not suitable to participate in the trial according to researchers.
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
China
 
 
NCT01391260
CS-S10-09
No
Not Provided
Not Provided
Zhu Guangying, Beijing Cancer Hospital
ZhuGuangYing
  • Beijing Cancer Hospital
  • Chinese Academy of Medical Sciences
  • Zhejiang Cancer Hospital
  • Fudan University
  • Renmin Hospital of Wuhan University
  • 307 Hospital of PLA
  • Beijing Clinical Service Center
Principal Investigator: Zhu Guangying Beijing Cancer Hospital
ZhuGuangYing
August 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP